Cancer isn’t driven by a single target.
Our therapies aren’t either.

We’re at #AACR26 this morning presenting DBXO-1, a multi-pMHC targeted T cell engager from Deck Bio.

Poster #1632 (Board 24), Section 10

#TCellEngagers #ImmunoOncology #TumorHeterogeneity